Who
Wendy F. Dicicco
Director
Company insider
Files Form 4 as: Director, EyePoint; Interim CFO, Akari Therapeutics; Director, SWK Holdings; Chief Financial Officer, Renovacor; Director, Coherent; Director, Cannapharmarx; CFO, Kensey Nash.
In numbers
- Trades disclosed
- 131
- Buys
- 6
- Sells
- 13
- Bought
- $68K
- Sold
- $2.1M
- Companies
- 7
- Companies where not an officer
- 4
- First trade
- 3 Jan 2006
- Last trade
- 2 Jan 2026
- Last filed
- 6 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 6 Jan 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 20 Aug 2024filed 21 Aug 2024 | EYPT EyePointBiotechnology | SEC FORM 4 Bought | $20K2,567 at $7.79 | filing |
| 1 May 2024filed 3 May 2024 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | —158,473,915 at $0.00 | filing |
| 5 Jan 2024filed 9 Jan 2024 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,014 at $0.00 | filing |
| 20 Jun 2023filed 22 Jun 2023 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,100 at $0.00 | filing |
| 20 Jun 2023filed 22 Jun 2023 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 9 Feb 2023filed 13 Feb 2023 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 9 Feb 2023filed 13 Feb 2023 | EYPT EyePointBiotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 30 Dec 2022filed 4 Jan 2023 | SWKHL SWK HoldingsConsumer & Specialty Finance | SEC FORM 4 Code A | $20K1,120 at $17.64 | filing |
| 30 Dec 2022filed 4 Jan 2023 | SWKHL SWK HoldingsConsumer & Specialty Finance | SEC FORM 4 Code A | $14K779 at $17.64 | filing |
| 1 Dec 2022filed 5 Dec 2022 | Renovacoroption or derivative | SEC FORM 4 Code D | —10,936 at $0.00 | filing |
| 1 Dec 2022filed 5 Dec 2022 | Renovacoroption or derivative | SEC FORM 4 Code D | —14,553 at $0.00 | filing |
| 1 Dec 2022filed 5 Dec 2022 | Renovacoroption or derivative | SEC FORM 4 Code D | —37,575 at $0.00 | filing |
| 1 Dec 2022filed 5 Dec 2022 | Renovacoroption or derivative | SEC FORM 4 Code D | —155,325 at $0.00 | filing |
| 1 Dec 2022filed 5 Dec 2022 | Renovacor | SEC FORM 4 Code D | —18,800 | filing |
| 1 Dec 2022filed 5 Dec 2022 | Renovacor | SEC FORM 4 Code A | —4,329 | filing |
| 1 Dec 2022filed 5 Dec 2022 | Renovacor | SEC FORM 4 Code D | —4,329 | filing |
| 30 Sep 2022filed 4 Oct 2022 | SWKHL SWK HoldingsConsumer & Specialty Finance | SEC FORM 4 Code A | $20K1,162 at $17.00 | filing |
News
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Jefferies Financial Group to "Hold"EYPT · tickerreport.com · 19 Oct 2026Coherent (COHR) Could Benefit From AI Networking Even if CPO Adoption Takes TimeCOHR · insidermonkey.com · 19 Oct 2026Optical Stocks Extend Slide as Money Rotates Into Defensives: Applied Optoelectronics Falls 6%, Coherent Drops 7%, Lumentum Slips 5%COHR · 247wallst.com · 15 Oct 2026Coherent Corp. Announces Timing of FY2027 First Quarter Earnings ReleaseCOHR · manilatimes.net · 14 Oct 2026Critical Review: Eyepoint Pharmaceuticals (NASDAQ:EYPT) and GSK (NYSE:GSK)EYPT · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Wendy F. Dicicco; 5 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.